Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Glossary Glossary
The Body Covers: The First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV
Session 5: Recent Cohort Studies

June 27, 1999

French researchers analyzed a cohort of 196 protease inhibitor (PI)-treated patients for factors associated with lipodystrophy, finding that the duration of nucleoside reverse transcriptase inhibitor (NRTI) treatment was associated with abnormalities. Using retrospective analysis, 49 of the patients were identified with either fat wasting (n = 14), truncal adiposity (n = 5) or both (n = 30). Comparing patients with lipodystrophy to those without lipodystrophy, the authors observed that lipid abnormalities were correlated with duration of infection, NRTI experience prior to highly active antiretroviral therapy (HAART), and HAART therapy. Patients with lipoatrophy tended to be younger and had greater exposure to NRTI prior to antiretroviral therapy compared to patients showing adiposity or fat wasting and adiposity. Patients with lipodystrophy also showed increased fasting triglycerides and cholesterol. However, patients without lipodystrophy also had increased fasting triglycerides and cholesterol over the same period.

The data indicate that duration of NRTI therapy is associated with fat wasting. The investigators also noted that elevated triglycerides and cholesterol are independent of lipodystrophy and may be related to PI-exposure, which contrasts with findings presented by Carr and colleagues.

Abstract: Lipodystrophic Syndromes in a Cohort of HIV-1 Infected Patients Receiving HAART with a Protease Inhibitor (PI)
Authored by: J.P. Viard and B. Rakotoambinina



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement